The role of dihydropyrimidine dehydrogenase expression in resistance to 5-fluorouracil in head and neck squamous cell carcinoma cells

Oral Oncology

Volumn 45, Issue 2, 2009, Pages 141-147

  Yasumatsu, Ryuji ^a   Nakashima, Torahiko ^a   Uryu, Hideoki ^b   Masuda, Muneyuki ^a   Hirakawa, Naoya ^a   Shiratsuchi, Hideki ^a   Tomita, Kichinobu ^b   Fukushima, Masakazu ^c   Komune, Shizuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

^c TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

5 Fluorouracil; Chemotherapy; Dihydropyrimidine dehydrogenase; Head and neck squamous cell carcinoma

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; CARBOPLATIN; CISPLATIN; COMPLEMENTARY DNA; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL;

ARTICLE; BIOLOGY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CARCINOMA CELL; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY MECHANISM; SQUAMOUS CELL CARCINOMA; TUMOR CELL;

ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL PROLIFERATION; DIHYDROURACIL DEHYDROGENASE (NADP); FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM PROTEINS; TUMOR CELLS, CULTURED;

EID: 58549087720     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2008.04.010     Document Type: Article

References (31)

1. Nishimura G., Tsukuda M., Horiuchi C., Satake K., Yoshida T., Nagao J., et al. Concurrent chemoradiotherapy for T4 patients with hypopharyngeal and laryngeal squamous cell carcinomas. Auris Nasus Larynx 34 4 (2007) 499-504
2. Longley D.B., Harkin D.P., and Johnston P.G. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3 5 (2003) 330-338
3. van Kuilenburg A.B. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40 7 (2004) 939-950
4. Kubota T. 5-Fluorouracil and dihydropyrimidine dehydrogenase. Int J Clin Oncol 8 3 (2003) 127-131
5. Salonga D., Danenberg K.D., Johnson M., Metzger R., Groshen S., Tsao-Wei D.D., et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6 4 (2000) 1322-1327
6. Ishikawa Y., Kubota T., Otani Y., Watanabe M., Teramoto T., Kumai K., et al. Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer. Anticancer Res 19 6C (1999) 5635-5640
7. Ishikawa Y., Kubota T., Otani Y., Watanabe M., Teramoto T., Kumai K., et al. Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil. Jpn J Cancer Res 91 1 (2000) 105-112
8. Huang C.L., Yokomise H., Kobayashi S., Fukushima M., Hitomi S., and Wada H. Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy. Int J Oncol 17 1 (2000) 47-54
9. Kobayashi H., Koike T., Nakatsuka A., Kurita H., Sagara J., Taniguchi S., et al. Dihydropyrimidine dehydrogenase expression predicts survival outcome and chemosensitivity to 5-fluorouracil in patients with oral squamous cell carcinoma. Oral Oncol 41 1 (2005) 38-47
10. Yoshinare K., Kubota T., Watanabe M., Wada N., Nishibori H., Hasegawa H., et al. Gene expression in colorectal cancer and in vitro chemosensitivity to 5-fluorouracil: a study of 88 surgical specimens. Cancer Sci 94 7 (2003) 633-638
11. Tuchman M., O'Dea R.F., Ramnaraine M.L., and Mirkin B.L. Pyrimidine base degradation in cultured murine C-1300 neuroblastoma cells and in situ tumors. J Clin Invest 81 2 (1988) 425-430
12. Fujiwaki R., Iida K., Nakayama K., Kanasaki H., Ozaki T., Hata K., et al. Dihydropyrimidine dehydrogenase in normal and malignant endometrium: relationship with cell proliferation and thymidine phosphorylase. Virchows Arch 443 5 (2003) 672-677
13. Ichikawa W., Takahashi T., Suto K., Nihei Z., Shirota Y., Shimizu M., et al. Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in relation to differentiation of gastric cancer. Int J Cancer 112 6 (2004) 967-973
14. Kawasaki G., Yoshitomi I., Yanamoto S., and Mizuno A. Thymidylate synthase and dihydropyrimidine dehydrogenase expression in oral squamous cell carcinoma: an immunohistochemical and clinicopathologic study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 94 6 (2002) 717-723
15. Kornmann M., Schwabe W., Sander S., Kron M., Strater J., Polat S., et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 9 11 (2003) 4116-4124
16. Sasaki E., Tominaga K., Kuwamura H., Watanabe T., Fujiwara Y., Oshitani N., et al. Synergistic antitumor effect of combined 5-fluorouracil (5-FU) with 5-chloro-2,4-dihydroxypyridine on 5-FU-resistant gastric cancer cells: possible role of a dihydropyrimidine dehydrogenase-independent mechanism. J Gastroenterol 42 10 (2007) 816-822
17. Mori K., Hasegawa M., Nishida M., Toma H., Fukuda M., Kubota T., et al. Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. Int J Oncol 17 1 (2000) 33-38
18. Yasumatsu R., Nakashima T., Hirakawa N., Kumamoto Y., Kuratomi Y., Tomita K., et al. Maspin expression in stage I and II oral tongue squamous cell carcinoma. Head Neck 23 11 (2001) 962-966
19. Yasumatsu R., Nakashima T., Azuma K., Hirakawa N., Kuratomi Y., Tomita K., et al. SCCA1 expression in T-lymphocytes peripheral to cancer cells is associated with the elevation of serum SCC antigen in squamous cell carcinoma of the tongue. Cancer Lett 167 2 (2001) 205-213
20. Chikamatsu K., Shino M., Sakakura K., Nakajima K., Sakurai T., Miyashita M., et al. Expression of thymidylate synthase and dihydropyrimidine dehydrogenase in adenoid cystic carcinoma of the head and neck: correlation with clinical outcome. Oral Oncol 43 7 (2007) 662-669
21. Etienne M.C., Cheradame S., Fischel J.L., Formento P., Dassonville O., Renee N., et al. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13 7 (1995) 1663-1670
22. Beck A., Etienne M.C., Cheradame S., Fischel J.L., Formento P., Renee N., et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 30A 10 (1994) 1517-1522
23. Hirano Y., Takayama T., Kageyama S., Ushiyama T., Suzuki K., and Fujita K. Thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma: relationship between histological parameters and chemosensitivity to 5-fluorouracil. Eur Urol 43 1 (2003) 45-51 (Discussion 51-2)
24. Shirasaka T., Nakano K., Takechi T., Satake H., Uchida J., Fujioka A., et al. Antitumor act0069vity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56 11 (1996) 2602-2606
25. Shirasaka T., Shimamato Y., Ohshimo H., Yamaguchi M., Kato T., Yonekura K., et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7 5 (1996) 548-557
26. Takechi T., Fujioka A., Matsushima E., and Fukushima M. Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer 38 9 (2002) 1271-1277
27. Oguri T., Achiwa H., Bessho Y., Muramatsu H., Maeda H., Niimi T., et al. The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells. Lung Cancer 49 3 (2005) 345-351
28. Fujiwara H., Terashima M., Irinoda T., Takagane A., Abe K., Nakaya T., et al. Superior antitumour activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity. Eur J Cancer 39 16 (2003) 2387-2394
29. Scotlandi K., Serra M., Manara M.C., Maurici D., Benini S., Nini G., et al. Clinical relevance of Ki-67 expression in bone tumors. Cancer 75 3 (1995) 806-814
30. Tsuji T., Sawai T., Takeshita H., Nakagoe T., Hidaka S., Yamaguchi H., et al. Tumor dihydropyrimidine dehydrogenase expression is a useful marker in adjuvant therapy with oral fluoropyrimidines after curative resection of colorectal cancer. Cancer Chemother Pharmacol 54 6 (2004) 531-536
31. Inoue K., Takao M., Watanabe F., Tarukawa T., Shimamoto A., Kaneda M., et al. Role of dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine against non-small cell lung cancer - in correlation with the tumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase. Lung Cancer 49 1 (2005) 47-54